医学
重症监护医学
背景(考古学)
贫血
中性粒细胞减少症
造血
发热性中性粒细胞减少症
化疗
血癌
操作化
癌症
肿瘤科
内科学
干细胞
古生物学
哲学
遗传学
认识论
生物
作者
Elizabeth A. Griffiths,Vivek Roy,Laura Alwan,Kimo Bachiashvili,John H. Baird,Rita Cool,Shira Dinner,Mark B. Geyer,John A. Glaspy,Ivana Gojo,Ashley Hicks,Avyakta Kallam,Wajih Zaheer Kidwai,Dwight D. Kloth,Eric H. Kraut,Daniel J. Landsburg,Gary H. Lyman,Anjlee Mahajan,Ryan Miller,Victoria Nachar
出处
期刊:Journal of The National Comprehensive Cancer Network
日期:2022-05-01
卷期号:20 (5): 436-442
被引量:71
标识
DOI:10.6004/jnccn.2022.0026
摘要
The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.
科研通智能强力驱动
Strongly Powered by AbleSci AI